

Non-Confidential Company Overview

Legal Disclaimer

Forward looking statement

This document is being provided for the sole purpose of providing the recipients with background information about the business of e-therapeutics plc (the Company).

The information, statements and opinions contained in this document do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of any offer to buy any securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments.

This document contains forward-looking statements including (without limitation) statements containing the words "believes", "expects", "estimates", "intends", "may", "plan", "will" and similar expressions (including the negative of those expressions). Forward-looking statements involve unknown risks, uncertainties and other factors which may cause the actual results, financial condition, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by those forward-looking statements. Given these uncertainties, you are cautioned not to place any undue reliance on those forward-looking statements. The forward-looking statements in this document are made on the date of this document. The Company and its directors are not under any obligation to update those forward-looking statements in this document to reflect actual future events or developments.

This document (including the information in this disclaimer) does not constitute an offer, invitation or recommendation to subscribe for or purchase any security. Neither the document, this disclaimer nor anything contained in them forms the basis of any contract or commitment. No representation or warranty, express or implied, is or will be made in relation to the accuracy or completeness of the information in this document and all and such responsibility and liability is expressly disclaimed.


This document shall not exclude any liability for, or remedy in respect of, fraudulent misrepresentation.

Company Overview

Driving innovation at the intersection of AI and precision medicine

Our mission:

Integrating computational power and biology to discover life-transforming medicines



Network biology pioneers. Unparalleled ability to model human biology and interrogate its complexity

Reproducible 100-1000x higher hit rate

Computational platform validated experimentally and through partnerships

Proprietary RNA interference platform

37 FTE Multi-disciplinary team >300M Data points **SiRNA** Gene silencing platform



Experienced Leadership



Ali Mortazavi Chief Executive Officer



Alan Whitmore Chief Scientific Officer



Alison Gallafent Head of IP



Jonny Wray Chief Technology Officer



Stephanie Maley Chief People Officer



Laura Roca-Alonso Chief Business Officer



Michael Bretherton Acting Interim Chief Financial Officer

Board of Directors Ali Mortazavi Chief Executive Officer

Professor Trevor Jones CBE

Non-Executive Chairman

Michael Bretherton

Non-executive Director CEO Sarossa Plc

Scientific Advisory Board Dr Paul Burke Chair, Former CTO, Pfizer

Professor John Mattick


Former CEO, Genomics England Professor RNA Biology, UNSW Sydney

Dr Bill Harte

Chief Translational Officer Case Western Reserve University

Business Model


Adaptable, hybrid business model to maximise the impact of our technologies



Biological Complexity Remains the Biggest Challenge

Oversimplification of the genotype-phenotype relationship contributes to drug failures


- Phenotype is an emergent
 property of molecular networks
- Molecular networks impart functional robustness to phenotype
- Networks are the mechanistic bridge between genotype and phenotype




Our way of Understanding and Modelling Biology

Capturing human complexity is key to the discovery of high-confidence drug candidates

Pathway models are too simplistic



Complexity captured



ETX proprietary metrics identify non-obvious as well as known mechanisms and targets. Our models enable superior *in silico* hypothesis generation and testing

Computational biology platform: ETX *in silico* Discovery Engine

Network & systems biology – core expertise of ETX

Network models are constructed and interrogated using ETX proprietary computational methods to provide insights into complex diseases and transform drug discovery

Biological complexity remains the big challenge in drug discovery and development. We strive to address it

- Biological functions are controlled by networks of genes and proteins
- Understanding these networks is key to understanding disease
- Millions of network models of disease processes built to ask therapeutic questions
- Ability to test millions of interventions in silico
- Computational outputs feed directly into translatable laboratory assays



Influenza virus replication



Endocytosis





Tunneling nanotube regulation



Lipid metabolism

Fibroblast activation



Angiogenic signaling

Axonal degeneration

Tryptophan catabolism



Telomerase signaling


Neuronal autophagy



Immune checkpoint signaling




Solid data foundations to enable unparalleled disease biology modelling and better drug discovery




ETX *in silico* **Discovery Engine** – **Inputs & Outputs**

Modular computational platform with multiple applications



Network Disruption – Assessing Compound/Target Impact



Impact on network integrity

Compound ranking 15M compound Al-enhanced annotated database

Significant impact on network structure and function

> 200-1,000 Compounds selected for screening in relevant, complex assays

Minimal impact on network structure and function

Biology First, Higher Hit Rates


Network models are constructed and interrogated using ETX proprietary computational methods to provide insights into complex diseases and transform drug discovery

	Disease agnostic projects	% 'Hits' confirmed in experimental phenotypic screens
e-therapeutics	Telomerase signalling	4.3%
	Hedgehog pathway	5.5%
	TNFα release	7.3%
	Influenza replication	2.2%
	Tryptophan catabolism	11%
	SIRS	11%
	Axonal degeneration	3.4%
	Reversal of T-cell exhaustion	5%
partners	Type 2 Diabetes	-
		-
	Idiopathic pulmonary fibrosis	-
	Applicable across diverse biology and therapeutic areas	High Bar 'Hit' Confirmed activity <10µM in multiple cell-based assays

biology and therapeutic areas

<10µM in multiple cell-based assays

No cytotoxicity | Structural QC | Initial FTO Good chemotypic diversity



Our hit rates are 100-1000x higher than industry standards

- Need to test fewer compounds to find high quality hits
- Improves translatability by enabling use of highly relevant phenotypic assays that better represent human disease at the screening stage
- Our hits are not 'blind' we use our Al-enhanced bioactivity data, network models and other AI-approaches alongside structural information in target deconvolution

Target ID from population genomics and other omics data

GAINs: Genome Associated Interaction Networks


Scope to identify novel targets beyond genetic variant lists

Analytics identify & group pathways that are:

- Important for the structure of the network
- Selective for the network
- Selective for the SNPs-genes
- Are not identifiable from the SNPs alone
- Close in 'network space'
- Likely to contribute to a common process

Proprietary approaches developed to deal with noise, error and bias

Network construction reveals the wider molecular context of the disease-associated proteins



Network-aware functional annotation

The Convergence of two Cutting-edge Platforms: Populating our inhouse RNAi Pipeline

ETX GalNAc-siRNA Platform Development

Equivalent performance to leading platforms demonstrated

New proprietary RNAi platform technology for liver gene silencing. Key advantages:

 Enables ETX to selectively silence any gene in hepatocytes



- GalNAc conjugation enables hepatocyte specificity
 and infrequent, subcutaneous administration
- Accelerated generation of new clinical candidates relative to other modalities


Key Aspects:

- Robust IP position 11 patent applications filed
- Extensive characterisation completed: 8 different construct designs tested across 3 target genes
- High hurdle for performance and safety benchmarking
- Significant in-house molecular design know-how
- Leveraging our **computational target ID capabilities (key differentiator)**. In-house pipeline upcoming


ETX GalNAc-siRNA Platform Performance: Headline Non-Human Primate (NHP) Results

Summary NHP target Y knock-down data (serum protein)

Different ETX constructs tested – Target Y




Competitive depth and duration of target knock-down



Cynomolgus monkeys, n=3


ETX lead Construct Design Performance and Safety (NHP)


Target Y liver mRNA and serum protein levels show deep and sustainable knock-down for 3 months




Cynomolgus monkeys, n=3, ALT (alanine aminotransferase), AST (aspartate aminotransferase)

Well tolerated in non-human primates






Hepatocyte-specific* Data Strategy and Knowledge Graph



Reproducible in other cell types

Hepatocyte Target Identification



Target identification is a key limitation in the field and the competitive landscape is highly overlapping. We leverage our computational platform to identify targets and are uniquely positioned to drive novelty, based on a better understanding of disease biology

Recent progress and Next Steps

Computational Platform:

- Expansion of target ID capabilities, including mode of action elucidation and target deconvolution capabilities
- Most complete hepatocyte-specific knowledge graph created
- Adaption and application of computational approaches to RNAi discovery
- Continued streamlining via increased automation and cloud computing
- **Galapagos collaboration:** Successfully identified hits (replicated 100-1000x higher hit rate) and 3 further milestone payments received. Scope for further upside throughout development and commercial
- New immuno-oncology collaboration started with iTeos Therapeutics
- **RNAi:** Proprietary GalNAc-siRNA platform technology developed and extensively characterised
 - Equivalent level of target gene knock-down and duration of action demonstrated against leading platforms
 - 11 patent applications filed to protect inventions
 - Ability to inhibit any gene in hepatocytes and rapidly generate drug candidates to prosecute target ideas

Next Steps:

- Generate **proprietary omics** hepatocyte data to feed into knowledge graph
- Continued development of **computational platform** for internal use and further collaborations
- Populate in-house **RNAi pipeline** and initiate partnering discussions



www.etherapeutics.co.uk